215 related articles for article (PubMed ID: 17451750)
1. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.
Dahari H; Lo A; Ribeiro RM; Perelson AS
J Theor Biol; 2007 Jul; 247(2):371-81. PubMed ID: 17451750
[TBL] [Abstract][Full Text] [Related]
2. Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.
Banerjee S; Keval R; Gakkhar S
Math Biosci; 2013 Oct; 245(2):235-48. PubMed ID: 23891586
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modeling of HCV infection and treatment.
Dahari H; Shudo E; Ribeiro RM; Perelson AS
Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
[TBL] [Abstract][Full Text] [Related]
4. New kinetic models for the hepatitis C virus.
Perelson AS; Herrmann E; Micol F; Zeuzem S
Hepatology; 2005 Oct; 42(4):749-54. PubMed ID: 16175615
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus kinetics.
Herrmann E; Neumann AU; Schmidt JM; Zeuzem S
Antivir Ther; 2000 Jun; 5(2):85-90. PubMed ID: 10971860
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of hepatitis C viral kinetics.
Zeuzem S
J Hepatol; 1999; 31 Suppl 1():61-4. PubMed ID: 10622562
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
[TBL] [Abstract][Full Text] [Related]
8. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
[TBL] [Abstract][Full Text] [Related]
9. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy.
Zeuzem S
Forum (Genova); 2000; 10(1):32-42. PubMed ID: 10717256
[TBL] [Abstract][Full Text] [Related]
12. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C viral dynamics.
Layden TJ; Lam NP; Wiley TE
Clin Liver Dis; 1999 Nov; 3(4):793-810. PubMed ID: 11291251
[TBL] [Abstract][Full Text] [Related]
15. Slow viral dynamics of hepatitis C virus genotype 4.
Halfon P; Neumann AU; Bourlière M; Rieu A; Chadapaud S; Khiri H; Ouzan D; Cacoub P
J Viral Hepat; 2003 Sep; 10(5):351-3. PubMed ID: 12969186
[TBL] [Abstract][Full Text] [Related]
16. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Guedj J; Dahari H; Rong L; Sansone ND; Nettles RE; Cotler SJ; Layden TJ; Uprichard SL; Perelson AS
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3991-6. PubMed ID: 23431163
[TBL] [Abstract][Full Text] [Related]
17. Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.
Rong L; Perelson AS
Math Biosci; 2013 Sep; 245(1):22-30. PubMed ID: 23684949
[TBL] [Abstract][Full Text] [Related]
18. Triphasic decline of hepatitis C virus RNA during antiviral therapy.
Dahari H; Ribeiro RM; Perelson AS
Hepatology; 2007 Jul; 46(1):16-21. PubMed ID: 17596864
[TBL] [Abstract][Full Text] [Related]
19. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
Chatterjee A; Guedj J; Perelson AS
Antivir Ther; 2012; 17(6 Pt B):1171-82. PubMed ID: 23186606
[TBL] [Abstract][Full Text] [Related]
20. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta.
Shiratori Y; Perelson AS; Weinberger L; Imazeki F; Yokosuka O; Nakata R; Ihori M; Hirota K; Ono N; Kuroda H; Motojima T; Nishigaki M; Omata M
J Hepatol; 2000 Aug; 33(2):313-22. PubMed ID: 10952250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
